| Literature DB >> 26695874 |
Young Hoon Roh1,2,3, Jason Z Deng1,2, Erik C Dreaden1,2, Jae Hyon Park3, Dong Soo Yun1,2, Kevin E Shopsowitz1,2, Paula T Hammond4,5.
Abstract
Packaging multiple small interfering RNA (siRNA) molecules into nanostructures at precisely defined ratios is a powerful delivery strategy for effective RNA interference (RNAi) therapy. We present a novel RNA nanotechnology based approach to produce multiple components of polymerized siRNA molecules that are simultaneously self-assembled and densely packaged into composite sponge-like porous microstructures (Multi-RNAi-MSs) by rolling circle transcription. The Multi-RNAi-MSs were designed to contain a combination of multiple polymeric siRNA molecules with precisely controlled stoichiometry within a singular microstructure by manipulating the types and ratios of the circular DNA templates. The Multi-RNAi-MSs were converted into nanosized complexes by polyelectrolyte condensation to manipulate their physicochemical properties (size, shape, and surface charge) for favorable delivery, while maintaining the multifunctional properties of the siRNAs for combined therapeutic effects. These Multi-RNAi-MS systems have great potential in RNAi-mediated biomedical applications, for example, for the treatment of cancer, genetic disorders, and viral infections.Entities:
Keywords: DNA/RNA nanotechnology; RNA interference; cancer; multifunctionality; siRNA delivery
Mesh:
Substances:
Year: 2015 PMID: 26695874 PMCID: PMC4768639 DOI: 10.1002/anie.201508978
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Figure 1Design and synthesis of multiple‐component RNAi microsponges (Multi‐RNAi‐MSs). A, B) Synthesis of Multi‐RNAi‐MSs with different types of circular DNA. A circular DNA library was constructed using individual circular DNA templates that encode each siRNA sequence. Numerous combinations of circular DNAs can be used to generate Multi‐RNAi‐MSs, depending on the application intended.
Figure 2Characterization of the Multi‐RNAi‐MSs. A) SEM image of a Multi‐RNAi‐MS. Scale bar: 1 μm. B) Confocal microscopy image of Multi‐RNAi‐MSs that had been functionalized with Cy5‐conjugated dUTP during the RCT process (red). The Multi‐RNAi‐MSs are shown in the middle section. Scale bar: 1 μm. C, D) TEM and cryo‐TEM images of Multi‐RNAi‐MSs at higher magnification. Scale bars: 200 nm.
Figure 3Characterization of Multi‐RNAi‐MSs obtained with the ratio control system. A) Confocal microscopy images of Multi‐RNAi‐MSs prepared according to the ratio control system. Five types of Multi‐RNAi‐MSs containing various amounts of polymeric RNAi molecules were synthesized by subjecting various combinations of circular DNA templates to RCT. The Multi‐RNAi‐MSs were hybridized with two fluorescent‐dye‐conjugated nucleic acid probes after the RCT process (yielding green or red fluorescence). Scale bars: 5 μm and 500 nm (inset). B) Flow cytometry analysis of the Multi‐RNAi‐MSs. The green channel indicates FITC and the red channel indicates APC. The R 2 value refers to the correlation between the observed green/red fluorescence intensity ratio and the pre‐determined green/red polymeric RNAi molar ratio.
Figure 4Characterization of Multi‐RNAi‐NPs after condensation. A,B) Confocal microscopy images confirming the co‐localization of multiple polymeric RNAi molecules (corresponding to green and red fluorescence, respectively) within Multi‐RNAi‐MSs and Multi‐RNAi‐NPs. C) TEM image of the Multi‐RNAi‐NPs. D) Confocal microscopy image of HeLa cells treated with Multi‐RNAi‐NPs. The Multi‐RNAi‐NPs had been labeled with Cy5‐conjugated UTP (red). The actin cytoskeleton was stained green with phalloidin, and the nucleus was stained blue with DAPI. Scale bar: 10 μm. E) The in vitro knockdown efficiency of GFP and RFP expression using PEI‐condensed Multi‐RNAi‐MSs was examined as a function of concentration. F) The viability of cancer cells after 48 hours of incubation with Multi‐RNAi‐NPs was determined in MTT assays. The relative viabilities were assessed by comparing the signals of treated cells to those of non‐treated control cells.